Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT study in idiopathic pulmonary fibrosis
NL-OMON27093Recruiting
- Sponsor
- BENEFIT Study Group
- Start
- Jul 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Remicade add-on with Placebo add-on (2 arms). Primary endpoints: Change in forced vital capacity from baseline and Time to disease progression. Started Jul 2004; status: recruiting.
02
Drugs
infliximab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON27093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27093.